Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Juan Li, Lin Lv, Yongjun Zhu, Zhihang Zhou & Song He. (2023) A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A Non-Inferiority Clinical Trial. Infection and Drug Resistance 16, pages 5637-5645.
Read now
Read now
Theodore Rokkas & Konstantinos Ekmektzoglou. (2023) Advances in the pharmacological and regulatory management of multidrug resistant Helicobacter pylori. Expert Review of Clinical Pharmacology 16:12, pages 1229-1237.
Read now
Read now
Amir Hossein Miri, Mojtaba Kamankesh, Mazda Rad-Malekshahi, Abbas Yadegar, Maryam Banar, Michael R. Hamblin, Ismaeil Haririan, Hamid Asadzadeh Aghdaei & Mohammad Reza Zali. (2023) Factors associated with treatment failure, and possible applications of probiotic bacteria in the arsenal against Helicobacter pylori. Expert Review of Anti-infective Therapy 21:6, pages 617-639.
Read now
Read now
Jinliang Xie, Dingwei Liu, Jianxiang Peng, Shuang Wu, Dongsheng Liu & Yong Xie. (2023) Iatrogenic factors of Helicobacter pylori eradication failure: lessons from the frontline. Expert Review of Anti-infective Therapy 21:4, pages 447-454.
Read now
Read now
Theodore Rokkas & David Y. Graham. (2023) How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert Review of Gastroenterology & Hepatology 17:1, pages 1-7.
Read now
Read now
Atul Kumar Singh, Santosh Maurya & Shashank Kumar. (2023) Repurposing FDA-approved anti-diabetic drug to target H. pylori peptidyl deformylase using computer-based drug discovery approach. Molecular Simulation 49:1, pages 124-132.
Read now
Read now
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li & Xingshun Qi. (2022) Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgraduate Medicine 134:7, pages 668-674.
Read now
Read now
Lyudmila Boyanova, Petyo Hadzhiyski, Nayden Kandilarov, Rumyana Markovska & Ivan Mitov. (2019) Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Review of Clinical Pharmacology 12:9, pages 909-915.
Read now
Read now
David Y. Graham, Maria Pina Dore & Hong Lu. (2018) Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Review of Anti-infective Therapy 16:9, pages 679-687.
Read now
Read now
Articles from other publishers (75)
Nur Izreena Ismail, Khairul Najmi Muhammad Nawawi, Deborah Chew Chia Hsin, Kok Wei Hao, Nik Ritza Kosai Nik Mahmood, Gary Lee Chong Chearn, Zhiqin Wong, Azmi Mohd Tamil, Hazel Joseph & Raja Affendi Raja Ali. (2023)
Probiotic containing
Lactobacillus reuteri DSM 17648
as an adjunct treatment for
Helicobacter pylori
infection: A randomized, double‐blind, placebo‐controlled trial
. Helicobacter 28:6.
Crossref
Crossref
Kaihao Lin, Lifang Huang, Yadong Wang, Kangkang Li, Yuanning Ye, Siqi Yang & Aimin Li. (2023)
Efficacy of genotypic susceptibility‐guided tailored therapy for
Helicobacter pylori
infection: A systematic review and single arm meta‐analysis
. Helicobacter 28:6.
Crossref
Crossref
Mohamed Hichem Loghmari, Firas Aissaoui, Arwa Guediche, Wided Bouhlel, Mejda Zakhama, Nabil B. Chaabene, Amel Rehaiem, Nouha Ben Abdeljalil, Manel Njima, Abdelfetteh Zakhama, Yosr Kadri, Maha Mastouri & Leila Safer. (2023)
Treatment of
Helicobacter pylori
infection 14‐day concomitant quadruple therapy versus triple therapy: A parallel double‐blind randomized controlled trial
. Health Science Reports 6:10.
Crossref
Crossref
Zahid Khan & Amresh Gul. (2023) Helicobacter Pylori-Associated Gastritis in Middle Eastern Patients: A Case Series. Cureus.
Crossref
Crossref
Yue Wang, Xue Wang, Xue-Yan Cao, Han-Long Zhu & Lin Miao. (2023) Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis. Frontiers in Cellular and Infection Microbiology 13.
Crossref
Crossref
Chunxi Shu, Zhou Xu, Cong He, Xinbo Xu, Yanan Zhou, Baihui Cai & Yin Zhu. (2023) Application of biomaterials in the eradication of Helicobacter pylori: A bibliometric analysis and overview. Frontiers in Microbiology 14.
Crossref
Crossref
Prabhav Kashyap Godavarthy & Chandra Puli. (2023) From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment. Cureus.
Crossref
Crossref
Hang Gong, Hui-Mei Xu & De-Kui Zhang. (2023) Focusing on Helicobacter pylori infection in the elderly. Frontiers in Cellular and Infection Microbiology 13.
Crossref
Crossref
Raluca Ioana Dascălu, Alexandra Bolocan, Dan Nicolae Păduaru, Alexandru Constantinescu, Magda Mihaela Mitache, Anca Daniela Stoica & Octavian Andronic. (2023) Multidrug resistance in Helicobacter pylori infection. Frontiers in Microbiology 14.
Crossref
Crossref
Luigi Gatta, Olga P. Nyssen, Giulia Fiorini, Ilaria Maria Saracino, Matteo Pavoni, Marco Romano, Antonietta Gerarda Gravina, Lucia Granata, Rinaldo Pellicano, Antonio Gasbarrini, Alfredo Di Leo, Giuseppe Losurdo, Francesco Franceschi, Gerardo Nardone, Alba Rocco, Maria Pina Dore, Fabio Farinati, Matteo Ghisa, Massimo Bellini, John Holton, Ignasi Puig, Dino Vaira, Claudio Borghi, Francis Mégraud, Colm O'Morain & Javier P. Gisbert. (2022)
Effectiveness of first and second‐line empirical treatment in Italy: Results of the European registry on
Helicobacter pylori
management
. United European Gastroenterology Journal 11:1, pages 103-113.
Crossref
Crossref
Xiaofen Bai, Minjie Zhu, Yajun He, Tengyan Wang, Da Tian & Jianchang Shu. (2022) The impacts of probiotics in eradication therapy of Helicobacter pylori. Archives of Microbiology 204:12.
Crossref
Crossref
Peiwei Li, Jing Jin, Yan Chen, Jianjuan Ma, Qin Du & Yuehua Han. (2022) Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy. Frontiers in Microbiology 13.
Crossref
Crossref
Yaobin Ouyang, Minghui Wang, Yu‐Ling Xu, Yin Zhu, Nong‐Hua Lu & Yi Hu. (2022)
Amoxicillin‐vonoprazan dual therapy for
Helicobacter pylori
eradication: A systematic review and meta‐analysis
. Journal of Gastroenterology and Hepatology 37:9, pages 1666-1672.
Crossref
Crossref
Jun-Hyung Cho & So-Young Jin. (2022)
Current guidelines for
Helicobacter pylori
treatment in East Asia 2022: Differences among China, Japan, and South Korea
. World Journal of Clinical Cases 10:19, pages 6349-6359.
Crossref
Crossref
Min Niu, Yan Zhou, Yunqian Xie, Xue Li, Yonggang Tian, Li Yao, Ximei Li, Hengjun Gao & Feihu Bai. (2022) Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori. Frontiers in Pharmacology 13.
Crossref
Crossref
Ying Liang, Jiaqian Yan, Ziqi Chen, Qing Gu & Ping Li. (2022) Antibacterial Effects of Bacteriocin PLNC8 against Helicobacter pylori and Its Potential Mechanism of Action. Foods 11:9, pages 1235.
Crossref
Crossref
Sameh S. Ali, Manar K. Abd Elnabi, Mohammad M. Alkherkhisy, Abdulkarim Hasan, Fanghua Li, Maha Khalil, Jianzhong Sun & Nessma El-Zawawy. (2022) Exploring the potential of Cinnamomum zeylanicum oil against drug resistant Helicobacter pylori-producing cytotoxic genes. Journal of Applied Biomedicine 20:1, pages 22-36.
Crossref
Crossref
Jeemyoung Kim, Eun Jeong Gong, Myeongsook Seo, Hyun Il Seo, Jong Kyu Park, Sang Jin Lee, Koon Hee Han, Woo Jin Jeong, Young Don Kim & Gab Jin Cheon. (2022) Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection. Journal of Personalized Medicine 12:1, pages 56.
Crossref
Crossref
Chi-Tan Hu. (2022) High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions. Tzu Chi Medical Journal 34:3, pages 303.
Crossref
Crossref
Yuting Lu, Huayi Liu, Kuo Yang, Yijia Mao, Lingkai Meng, Liu Yang, Guangze Ouyang & Wenjie Liu. (2022) A comprehensive update: gastrointestinal microflora, gastric cancer and gastric premalignant condition, and intervention by traditional Chinese medicine胃肠菌群、胃癌及癌前病变与中药防治的最新研究进展. Journal of Zhejiang University-SCIENCE B 23:1, pages 1-18.
Crossref
Crossref
Evariste Tshibangu-Kabamba & Yoshio Yamaoka. (2021) Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications. Nature Reviews Gastroenterology & Hepatology 18:9, pages 613-629.
Crossref
Crossref
M Nkuize, J Vanderpas, M Buset, M Delforge, G‐B Cadière & S Wit. (2021)
Failure to eradicate
Helicobacter pylori
infection is more frequent among HIV‐positive patients
. HIV Medicine 22:7, pages 547-556.
Crossref
Crossref
Zhan-Yue Niu, Si-Zhu Li, Yan-Yan Shi & Yan Xue. (2021)
Effect of gastric microbiota on quadruple
Helicobacter pylori
eradication therapy containing bismuth
. World Journal of Gastroenterology 27:25, pages 3913-3924.
Crossref
Crossref
Suat Moi Puah, Khean Lee Goh, Heng Kang Ng & Kek Heng Chua. (2021)
Current status of
Helicobacter pylori
resistance to Clarithromycin and Levofloxacin in Malaysia—findings from a molecular based study
. PeerJ 9, pages e11518.
Crossref
Crossref
Carmelo Scarpignato & Richard H. Hunt. (2021) Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Current Treatment Options in Gastroenterology 19:1, pages 94-132.
Crossref
Crossref
宁 王. (2021) Application Progress of Minocycline in Helicobacter pylori Eradication Program. Advances in Clinical Medicine 11:12, pages 6093-6096.
Crossref
Crossref
Bojan Tepes, Natasa Brglez Jurecic, Katja Tepes, Marta Espada Sanchez, Olga Perez Nyssen, Colm O’Morain, Francis Mégraud & Javier Gisbert. (2021) <b><i>Helicobacter pylori</i></b> Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on <b><i>H. pylori</i></b> Management. Digestive Diseases 39:4, pages 318-324.
Crossref
Crossref
Siti Boedina Kresno. (2020) Cancer Risk Assessment and Screening; A Challenge for Clinical Pathology Service?. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 27:1, pages 97-103.
Crossref
Crossref
Ilaria M. Saracino, Matteo Pavoni, Angelo Zullo, Giulia Fiorini, Laura Saccomanno, Tiziana Lazzarotto, Guido Antonelli, Rossana Cavallo, Claudio Borghi & Dino Vaira. (2020) Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 81, pages 50-53.
Crossref
Crossref
David Y. Graham. (2020) Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics 9:10, pages 671.
Crossref
Crossref
Alex Hwong‐Ruey Leow, Jo‐Ven Chang & Khean‐Lee Goh. (2020)
Searching for an optimal therapy for
H pylori
eradication: High‐dose proton‐pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days
. Helicobacter 25:5.
Crossref
Crossref
Yunzhi Zou, Xing Qian, Xiaoqun Liu, YanPing Song, Conghua Song, Shuang Wu, Ying An, Rui Yuan, Youhua Wang & Yong Xie. (2020)
The effect of antibiotic resistance on
Helicobacter pylori
eradication efficacy: A systematic review and meta‐analysis
. Helicobacter 25:4.
Crossref
Crossref
Wagih A. El-Shouny, Sameh S. Ali, Hegazy M. Hegazy, Manar K. Abd Elnabi, Asmaa Ali & Jianzhong Sun. (2020) Syzygium aromaticum L.: Traditional herbal medicine against cagA and vacA toxin genes-producing drug resistant Helicobacter pylori. Journal of Traditional and Complementary Medicine 10:4, pages 366-377.
Crossref
Crossref
Yi Zhang, Yang-Jie Zhu, Zhe Zhao, Jing-Tao Zhao, Ting-Yi Wang, Jing Yang, Dong-Feng Chen & Chun-Hui Lan. (2020) Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. European Journal of Gastroenterology & Hepatology 32:5, pages 563-568.
Crossref
Crossref
Nan Phyu Sin Toe Myint, Thet Tun Zaw, Kyauk Sain, Soe Waiyan, Mark Danta, David Cooper, Ne Myo Aung, Mar Mar Kyi & Josh Hanson. (2019)
Sequential
Helicobacter pylori
eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability
. Journal of Gastroenterology and Hepatology 35:4, pages 617-623.
Crossref
Crossref
Saracino I.M., Pavoni M., Zullo A.Fiorini G.Saccomanno L.Lazzarotto T.Cavallo R.Antonelli G.Vaira D.. (2020) Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients. Antibiotics 9:3, pages 121.
Crossref
Crossref
Sandra Salillas & Javier Sancho. (2020) Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens. International Journal of Molecular Sciences 21:5, pages 1881.
Crossref
Crossref
Masaki Murata, Mitsushige Sugimoto, Hitomi Mizuno, Takeshi Kanno & Kiichi Satoh. (2020) Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. Journal of Clinical Medicine 9:2, pages 543.
Crossref
Crossref
Yang-Jie Zhu, Yi Zhang, Ting-Yi Wang, Jing-Tao Zhao, Zhe Zhao, Jian-Ru Zhu & Chun-Hui Lan. (2020)
High dose PPI-amoxicillin dual therapy for the treatment of
Helicobacter pylori
infection: a systematic review with meta-analysis
. Therapeutic Advances in Gastroenterology 13, pages 175628482093711.
Crossref
Crossref
Shria Kumar, Ravindra Sangitha, Irving Nachamkin & David C. Metz. (2020)
Resistance patterns of refractory
Helicobacter pylori
infection in a referral centre in the Delaware Valley
. GastroHep 2:1, pages 6-12.
Crossref
Crossref
Beom Jin Kim, Chang‐Hun Yang, Hyun Joo Song, Seong Woo Jeon, Gwang Ha Kim, Hyun‐Soo Kim, Tae Ho Kim, Ki‐Nam Shim, Il‐Kwun Chung, Moo In Park, Il Ju Choi, Ji Hyun Kim, Byung‐Wook Kim, Gwang Ho Baik, Sok Won Han, Hyang Eun Seo, Woon Tae Jung, Jung Hwan Oh, Sang Gyun Kim, Jun Haeng Lee, Sue K. Park, Byung‐Joo Park, Bo Ram Yang, Joongyub Lee & Jae G. Kim. (2019)
Online registry for nationwide database of
Helicobacter pylori
eradication in Korea: Correlation of antibiotic use density with eradication success
. Helicobacter 24:5.
Crossref
Crossref
Lei Gu, Shenglan Li, Ying He, Yi Chen, Yanzhi Jiang, Yu Peng, Xiaowei Liu & Huixiang Yang. (2019)
Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line
Helicobacter pylori
therapy in clinical practice: A pilot study
. Helicobacter 24:4.
Crossref
Crossref
Carlo A. Fallone, Steven F. Moss & Peter Malfertheiner. (2019) Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology 157:1, pages 44-53.
Crossref
Crossref
Jing Yin, Jinyu Yi, Chun Yang, Bo Xu, Jiang Lin, Hongyi Hu, Xiaojun Wu, Hailian Shi & Xiaoyan Fei. (2019)
Weiqi Decoction Attenuated Chronic Atrophic Gastritis with Precancerous Lesion through Regulating Microcirculation Disturbance and HIF-1
Signaling Pathway
. Evidence-Based Complementary and Alternative Medicine 2019, pages 1-12.
Crossref
Crossref
Qi Chen, Xiaohua Long, Yingjie Ji, Xiao Liang, Dongping Li, Hong Gao, Beili Xu, Ming Liu, Ying Chen, Yunwei Sun, Yan Zhao, Gang Xu, Yanyan Song, Lou Yu, Wei Zhang, Wenzhong Liu, David Y. Graham & Hong Lu. (2019)
Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line
Helicobacter pylori
treatment
. Alimentary Pharmacology & Therapeutics 49:11, pages 1385-1394.
Crossref
Crossref
Naoki Chiba. 2019. Evidence‐based Gastroenterology and Hepatology 4e. Evidence‐based Gastroenterology and Hepatology 4e
68
85
.
Kláudia Maria Machado Neves Silva, Diogo Émerson Leite de Carvalho, Vânia Maria Moreira Valente, Juan Carlos Campos Rubio, Paulo Eustáquio Faria & Priscila Pereira Silva-Caldeira. (2019) Concomitant and controlled release of furazolidone and bismuth(III) incorporated in a cross-linked sodium alginate-carboxymethyl cellulose hydrogel. International Journal of Biological Macromolecules 126, pages 359-366.
Crossref
Crossref
Jing Yang, Yi Zhang, Ling Fan, Yang-Jie Zhu, Ting-Yi Wang, Xing-Wei Wang, Dong-Feng Chen & Chun-Hui Lan. (2019) Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. American Journal of Gastroenterology 114:3, pages 437-445.
Crossref
Crossref
Vincenzo De Francesco, Angelo Zullo, Giulia Fiorini, Ilaria M Saracino, Matteo Pavoni & Dino Vaira. (2019)
Role of MIC levels of resistance to clarithromycin and metronidazole in
Helicobacter pylori
eradication
. Journal of Antimicrobial Chemotherapy 74:3, pages 772-774.
Crossref
Crossref
Dong-Min Yi, Tao-Tao Yang, Shuai-Heng Chao, Ya-Xin Li, Ying-Lei Zhou, Hai-Hui Zhang, Ling Lan, Yu-Wei Zhang, Xue-Mei WangYan-Rui Zhang, Jian Li & Song-Ze Ding. (2019) Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine 98:6, pages e14408.
Crossref
Crossref
Jin-Su Jun, Ji-Hyun Seo, Ji-Sook Park, Kwang-Ho Rhee & Hee-Shang Youn. (2019)
Changes in the Treatment Strategies for
Helicobacter pylori
Infection in Children and Adolescents in Korea
. Pediatric Gastroenterology, Hepatology & Nutrition 22:5, pages 417.
Crossref
Crossref
Jorge Alfredo Morcillo-Muñoz, William Alberto Regino-Otero & Martín Alonso Gómez Zuleta. (2018) Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?. Revista Colombiana de Gastroenterología 33:4, pages 437.
Crossref
Crossref
Yao‐Bin Yang‐Ou, Yi Hu, Yin Zhu & Nong‐Hua Lu. (2018)
The effect of antioxidants on
Helicobacter pylori
eradication: A systematic review with meta‐analysis
. Helicobacter 23:6.
Crossref
Crossref
Alex H.‐R. Leow, Ahmad N. Azmi, Mun‐Fai Loke, Jamuna Vadivelu, David Y. Graham & Khean‐Lee Goh. (2018)
Optimizing first line 7‐day standard triple therapy for
Helicobacter pylori
eradication: Prolonging treatment or adding bismuth: which is better?
. Journal of Digestive Diseases 19:11, pages 674-677.
Crossref
Crossref
Yong Xie, Zhenyu Zhang, Junbo Hong, Wenzhong Liu, Hong Lu, Yiqi Du, Weihong Wang, Jianming Xu, Xuehong Wang, Lijuan Huo, Guiying Zhang, Chunhui Lan, Xiaoyan Li, Yanqing Li, Hong Wang, Guoxin Zhang, Yin Zhu, Xu Shu, Ye Chen, Jiangbin Wang & Nonghua Lu. (2018)
Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for
Helicobacter pylori
infection: A multicenter randomized controlled trial in China
. Helicobacter 23:5.
Crossref
Crossref
Jyh-Ming Liou, Po-Yueh Chen, Jiing-Chyuan Luo, Ji-Yuh Lee, Chieh-Chang Chen, Yu-Jen Fang, Tsung-Hua Yang, Chi-Yang Chang, Ming-Jong Bair, Mei-Jyh Chen, Yao-Chun Hsu, Wen-Feng Hsu, Chun-Chao Chang, Jaw-Town Lin, Chia-Tung Shun, Emad M. El-Omar, Ming-Shiang Wu, Jyh-Ming Liou, Yi-Chia Lee, Jaw-Town Lin, Chun-Ying Wu, Jeng-Yih Wu, Ching-Chow Chen, Chun-Hung Lin, Yu-Ren Fang, Ming-Jong Bair, Jiing-Chyuan Luo, Ming-Shiang Wu, Tsu-Yao Cheng, Ping-Huei Tseng, Han-Mo Chiu, Chun-Chao Chang, Chien-Chun Yu, Min-Chin Chiu, Yen-Nien Chen, Wen-Hao Hu, Chu-Kuang Chou, Chi-Ming Tai, Ching-Tai Lee, Wen-Lun Wang & Wen-Shiung Chang. (2018) Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology 155:4, pages 1109-1119.
Crossref
Crossref
Amin Talebi Bezmin Abadi & Yoshio Yamaoka. (2018) Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 14, pages 111-117.
Crossref
Crossref
Ante Tonkic, Jonatan Vukovic, Pavle Vrebalov Cindro, Valdi Pesutic Pisac & Marija Tonkic. (2018) Diagnosis of Helicobacter pylori infection. Wiener klinische Wochenschrift 130:17-18, pages 530-534.
Crossref
Crossref
L. Gatta & C. Scarpignato. (2018)
Editorial:
Helicobacter pylori
resistance and sequential therapy-authors’ reply
. Alimentary Pharmacology & Therapeutics 48:1, pages 96-97.
Crossref
Crossref
Erica A. Golemis, Paul Scheet, Tim N. Beck, Eward M. Scolnick, David J. Hunter, Ernest Hawk & Nancy Hopkins. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes & Development 32:13-14, pages 868-902.
Crossref
Crossref
Hashem B. El-Serag, John Y. Kao, Fasiha Kanwal, Mark Gilger, Frank LoVecchio, Steven F. Moss, Sheila Crowe, Adam Elfant, Thomas Haas, Ronald J. Hapke & David Y. Graham. (2018) Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology 16:7, pages 992-1002.e6.
Crossref
Crossref
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du & Nong Hua Lu. (2018)
Fifth Chinese National Consensus Report on the management of
Helicobacter pylori
infection
. Helicobacter 23:2.
Crossref
Crossref
I. G. Bakulin, S. S. Pirogov, N. V. Bakulina, E. A. Stadnik & N. N. Golubev. (2018) Prophylaxis and early diagnosis of stomach cancer. Dokazatel'naya gastroenterologiya 7:2, pages 44.
Crossref
Crossref
Bojan Tepes, Marko Kastelic, Miroslav Vujasinovic, Polona Lampic, Maja Seruga, Natasa Brglez Jurecic, Olga P. Nyssen, Maria G. Donday, Colm O’Morain, Francis Megraud, Adrian G McNicholl & Javier P. Gisbert. (2017) Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management. Radiology and Oncology 52:1, pages 1-6.
Crossref
Crossref
David Y Graham. (2017)
Illusions regarding
Helicobacter pylori
clinical trials and treatment guidelines
. Gut 66:12, pages 2043-2046.
Crossref
Crossref
Ritsuko Oikawa, Yoshiyuki Watanabe, Shuichi Miyamoto, Yoshinori Sato, Shoko Ono, Katsuhiro Mabe, Hiroyuki Yamamoto, Mototsugu Kato & Fumio Itoh. (2017)
Enrichment of
Helicobacter pylori
mutant strains after eradication therapy analyzed by gastric wash–based quantitative pyrosequencing
. Tumor Biology 39:10, pages 101042831773486.
Crossref
Crossref
Marjan Mohammadi, Bahareh Attaran, Reza Malekzadeh & David Y. Graham. (2017) Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Digestive Diseases and Sciences 62:8, pages 1890-1896.
Crossref
Crossref
Yanghee Woo, Carolyn E. Behrendt, Garrick Trapp, Jae Geun Hyun, Tamas Gonda, Yuman Fong & Timothy Wang. (2017)
Screening endoscopy finds high prevalence of
Helicobacter pylori
and intestinal metaplasia in Korean American with limited access to health care
. Journal of Surgical Oncology 116:2, pages 172-176.
Crossref
Crossref
Yi Hu, Yin Zhu & Nong-Hua Lu. (2017) Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 7.
Crossref
Crossref
Bich N. Dang & David Y. Graham. (2017) Helicobacter pylori infection and antibiotic resistance: a WHO high priority?. Nature Reviews Gastroenterology & Hepatology 14:7, pages 383-384.
Crossref
Crossref
Yi Hu, Yin Zhu & Nong-hua Lu. (2017) Primary Antibiotic Resistance of Helicobacter pylori in China. Digestive Diseases and Sciences 62:5, pages 1146-1154.
Crossref
Crossref
Amin Talebi Bezmin Abadi. (2017) Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 8, pages 123-130.
Crossref
Crossref
D N Andreev, D T Dicheva & I V Maev. (2017) Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii arkhiv 89:2, pages 84-90.
Crossref
Crossref
Hiroshi Matsumoto, Akiko Shiotani, Ryo Katsumata, Minoru Fujita, Rui Nakato, Takahisa Murao, Manabu Ishii, Tomoari Kamada, Ken Haruma & David Y. Graham. (2016) Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Digestive Diseases and Sciences 61:11, pages 3215-3220.
Crossref
Crossref
David Y. Graham & Loren Laine. (2016) The Toronto Helicobacter pylori Consensus in Context. Gastroenterology 151:1, pages 9-12.
Crossref
Crossref